Drugs News and Research

RSS

Tillotts Pharma to purchase global rights for AstraZeneca’s Entocort excluding the U.S.

Tillotts Pharma AG, part of the Zeria Group, announced today that it has entered into an agreement for the acquisition of the global rights for Entocort (budesonide) from AstraZeneca, excluding the U.S., which will remain with AstraZeneca.

9 Jul 2015

TSRI study reveals alternative approach to current anti-HIV strategies

HIV-infected patients remain on antiretroviral therapy for life because the virus survives over the long-term in infected dormant cells. Interruption of current types of antiretroviral therapy results in a rebound of the virus and clinical progression to AIDS.

9 Jul 2015

Globavir agrees to exclusively license novel oncology compound to Sorrento Therapeutics

Globavir Biosciences, Inc., a specialty biotechnology company developing small molecule drugs to treat cancer and infectious diseases, and Sorrento Therapeutics, Inc., an oncology company developing new treatments for cancer and associated pain, announced today that the companies have entered into an agreement under which Globavir exclusively licensed its novel oncology compound, BC001, to Sorrento Therapeutics.

9 Jul 2015

FDA approves new heart failure drug

A new drug called Entresto has been approved by the U.S Food and Drug Administration (FDA) for the treatment of heart failure.

9 Jul 2015

Sorrento, NantBioScience form joint venture to develop targeted therapies against cancer

Sorrento Therapeutics, Inc. and NantBioScience, Inc., a majority owned subsidiary of NantWorks, LLC, announced today that they have established a joint venture to focus on the development of 'first-in-class' small molecules against targets that have eluded the pharmaceutical industry to date and which may address important drivers of cancer growth including cancer stem cells.

9 Jul 2015

Up-to-date treatment and diagnostic guidelines for diabetic retinal degeneration

Around 600,000 Austrians suffer from diabetes. This condition is frequently associated with serious retinal disorders. Along with age-related macular degeneration, diabetic retinal degeneration is one of the most common causes of blindness. The Department of Ophthalmology and Optometry at MedUni Vienna was chosen by the European Society of Retina Specialists (EURETINA) to coordinate the development of up-to-date treatment and diagnostic guidelines.

9 Jul 2015

Graphene coating can help boost chemotherapy treatment

Silver is often used as a coating on medical equipment used for chemotherapy. The problem is that this silver coating can break down drugs. Now, researchers have found a graphene coating that will help boost chemotherapy's effects.

9 Jul 2015

Johns Hopkins, IOCB Prague sign drug discovery research agreement

The Johns Hopkins Drug Discovery (JHDD) program, created with the mission of identifying novel drug targets arising from Johns Hopkins faculty research and translating them into new therapeutics, and the Institute of Organic Chemistry and Biochemistry, The Czech Academy of Sciences (IOCB Prague) have entered into a five-year drug discovery research agreement to develop small-molecule and peptide drugs for a range of therapeutic areas including neurological diseases, cancer and gastrointestinal disorders.

9 Jul 2015

Phase 3 ODYSSEY JAPAN trial of Praluent injection meets primary endpoint

Regeneron Pharmaceuticals, Inc. and Sanofi today announced that the Phase 3 ODYSSEY JAPAN trial of the investigational therapy Praluent® (alirocumab) Injection met its primary endpoint.

9 Jul 2015

Vanderbilt investigators develop potential antibody treatments against chikungunya

In late 2013 the Caribbean had its first case of the mosquito-borne chikungunya virus. Today there have been almost 1.2 million cases in 44 countries or territories, including 177 cases in 31 U.S. States. Vanderbilt University Medical Center's James Crowe, M.D., Ann Scott Carell Professor and director of the Vanderbilt Vaccine Center, and his team are reporting the first large panel of antibody treatments against this disease in the current issue of Cell Host and Microbe.

9 Jul 2015

Guselkumab drug more effective than current standard of care for psoriasis

A phase II clinical trial led by Northwestern Medicine investigators shows that a new psoriasis drug called guselkumab has greater efficacy than the current standard of care for the chronic skin condition.

9 Jul 2015

Partnerships between healthcare insurers and pharmaceutical companies promote real-world value

PwC's Health Research Institute (HRI) reports that market forces are driving new sector collaborations– pairing traditional drug makers with insurers, health systems, patient groups and technology firms – to maximize real-world value and health outcomes.

9 Jul 2015

MGH investigators report that medication could augment benefits of bariatric surgery

New findings about the mechanisms involved - or not involved - in the effects of the most common form of bariatric surgery suggest that combining surgery with a specific type of medication could augment the benefits of the procedure. In a report that has been published online in the journal Endocrinology, Massachusetts General Hospital investigators report that the effects of Roux-en-Y gastric bypass (RYGB) do not utilize neurologic pathways controlled by the serotonin 2C receptor.

9 Jul 2015

Computer model shows how cancerous tumors manipulate blood-vessel growth for their own benefit

Rice University researchers have built a simulation to show how cancerous tumors manipulate blood-vessel growth for their own benefit.

9 Jul 2015

Progesterone hormone can benefit breast cancer patients

AROUND half of all breast cancer patients could one day benefit from having the cheap and widely-available female hormone progesterone added to their treatment, according to Cancer Research UK funded research published in Nature today (Thursday).

9 Jul 2015

UK study suggests new approach to develop highly-potent drugs

A new study led by University of Kentucky researchers suggests a new approach to develop highly-potent drugs which could overcome current shortcomings of low drug efficacy and multi-drug resistance in the treatment of cancer as well as viral and bacterial infections.

9 Jul 2015

New research identifies potential treatment for primary effusion lymphoma

New research from the University of Southern California Norris Comprehensive Cancer Center has identified a potential treatment for a rare but previously incurable form of lymphoma that is observed primarily in patients with HIV/AIDS infection.

8 Jul 2015

Ludwig, CRI launch clinical trials to evaluate immunotherapies for treatment of GBM and solid tumors

Ludwig Cancer Research and the Cancer Research Institute have launched clinical trials evaluating an immunotherapy for the treatment of the brain cancer glioblastoma multiforme (GBM), and a combination of immunotherapies for a variety of solid tumors.

8 Jul 2015

Aridis expands, accelerates current AR-301 Phase 2a study for treatment of acute pneumonia in the U.S.

Aridis Pharmaceuticals, Inc., a biopharmaceutical company applying proprietary technologies to produce novel anti-infectives and immunotherapies for infectious diseases, announced today that the U.S. Food and Drug Administration has accepted its Investigational New Drug (IND) application for AR-301, also referred to as Salvecin, the company's fully human anti-Staphylococcal α-toxin IgG1 monoclonal antibody being developed for the treatment of hospital-acquired and ventilator-associated pneumonia (HAP and VAP) caused by Staphylococcus aureus, including multi-drug resistant 'MRSA' strains.

8 Jul 2015

Exercise program for older adults with osteoarthritis may soon be covered by Medicare

Fit & Strong!, an exercise program tailored to break the cycle of weakening and pain in older adults with osteoarthritis and developed at the University of Illinois at Chicago, may soon be covered by Medicare.

8 Jul 2015

Drugs News and Research

Tillotts Pharma to purchase global rights for AstraZeneca’s Entocort excluding the U.S.

TSRI study reveals alternative approach to current anti-HIV strategies

Globavir agrees to exclusively license novel oncology compound to Sorrento Therapeutics

FDA approves new heart failure drug

Sorrento, NantBioScience form joint venture to develop targeted therapies against cancer

Up-to-date treatment and diagnostic guidelines for diabetic retinal degeneration

Graphene coating can help boost chemotherapy treatment

Johns Hopkins, IOCB Prague sign drug discovery research agreement

Phase 3 ODYSSEY JAPAN trial of Praluent injection meets primary endpoint

Vanderbilt investigators develop potential antibody treatments against chikungunya

Guselkumab drug more effective than current standard of care for psoriasis

Partnerships between healthcare insurers and pharmaceutical companies promote real-world value

MGH investigators report that medication could augment benefits of bariatric surgery

Computer model shows how cancerous tumors manipulate blood-vessel growth for their own benefit

Progesterone hormone can benefit breast cancer patients

UK study suggests new approach to develop highly-potent drugs

New research identifies potential treatment for primary effusion lymphoma

Ludwig, CRI launch clinical trials to evaluate immunotherapies for treatment of GBM and solid tumors

Aridis expands, accelerates current AR-301 Phase 2a study for treatment of acute pneumonia in the U.S.

Exercise program for older adults with osteoarthritis may soon be covered by Medicare

Bringing real-time analytics to downstream bioprocess monitoring

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Latest News